PMID- 27484986
OWN - NLM
STAT- MEDLINE
DCOM- 20170406
LR  - 20181113
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 14
IP  - 3
DP  - 2016 Sep
TI  - Therapeutic effects of paeonol on 
      methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease 
      in mice.
PG  - 2397-404
LID - 10.3892/mmr.2016.5573 [doi]
AB  - Paeonol is a major phenolic compound of the Chinese herb, Cortex Moutan, and is 
      known for its antioxidant, anti-inflammatory and antitumor properties. The 
      present study was designed to investigate the therapeutic potential and 
      underlying mechanisms of paeonol on a 
      1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid (MPTP/p)-induced mouse 
      model of Parkinson's disease (PD). MPTP (25 mg/kg), followed by probenecid 
      (250 mg/kg), was administered via i.p. injection for five consecutive days to 
      induce the mouse model of PD. Paeonol (20 mg/kg) was administrated orally for 
      21 days. Behavior was assessed using the rotarod performance and open‑field 
      tests. Additionally, the levels of tyrosine hydroxylase (TH), microglia, 
      interleukin‑1beta (IL‑1beta), and brain‑derived neurotrophic factor (BDNF) in the 
      substantia nigra pars compacta (SNpc) were evaluated by immunohistochemical 
      staining. MPTP/p‑induced motor deficits were observed to be significantly 
      improved following long‑term treatment with paeonol. Paeonol treatment decreased 
      MPTP/p‑induced oxidative stress, as determined by evaluating the activity levels 
      of superoxide dismutase, catalase and glutathione. Additionally, MPTP/p‑induced 
      neuroinflammation was assessed by examining the levels of microglia and IL‑1beta, 
      which were significantly decreased following paeonol treatment. Paeonol treatment 
      improved the MPTP/p‑induced dopaminergic neurodegeneration, as measured by 
      observing the increased TH level in the SNpc. Furthermore, the BDNF level was 
      significantly elevated in the paeonol treatment group compared with mice treated 
      with MPTP/p only. In conclusion, paeonol exerted therapeutic effects in the 
      MPTP/p‑induced mouse model of PD, possibly by decreasing the damage from 
      oxidative stress and neuroinflammation, and by enhancing the neurotrophic effect 
      on dopaminergic neurons. The results demonstrate paeonol as a potential novel 
      treatment for PD.
FAU - Shi, Xiaojin
AU  - Shi X
AD  - Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, 
      Bengbu, Anhui 233004, P.R. China.
FAU - Chen, Yu-Hua
AU  - Chen YH
AD  - Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, 
      Bengbu, Anhui 233004, P.R. China.
FAU - Liu, Hao
AU  - Liu H
AD  - Department of Pharmacy, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China.
FAU - Qu, Hong-Dang
AU  - Qu HD
AD  - Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, 
      Bengbu, Anhui 233004, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20160728
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Acetophenones)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Neuroprotective Agents)
RN  - 3R834EPI82 (paeonol)
RN  - 9P21XSP91P (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
RN  - PO572Z7917 (Probenecid)
SB  - IM
MH  - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/*adverse effects
MH  - Acetophenones/chemistry/*pharmacology
MH  - Animals
MH  - Behavior, Animal
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Disease Models, Animal
MH  - Dopaminergic Neurons/drug effects/metabolism/pathology
MH  - Drugs, Chinese Herbal/chemistry/pharmacology
MH  - Immunohistochemistry
MH  - Male
MH  - Mice
MH  - Neuroprotective Agents/pharmacology
MH  - Oxidative Stress/drug effects
MH  - Parkinson Disease/diagnosis/drug therapy/*etiology/*metabolism
MH  - Probenecid/*adverse effects
MH  - Rotarod Performance Test
MH  - Tyrosine 3-Monooxygenase/metabolism
PMC - PMC4991680
EDAT- 2016/08/04 06:00
MHDA- 2017/04/07 06:00
PMCR- 2016/07/28
CRDT- 2016/08/04 06:00
PHST- 2015/08/27 00:00 [received]
PHST- 2016/05/18 00:00 [accepted]
PHST- 2016/08/04 06:00 [entrez]
PHST- 2016/08/04 06:00 [pubmed]
PHST- 2017/04/07 06:00 [medline]
PHST- 2016/07/28 00:00 [pmc-release]
AID - mmr-14-03-2397 [pii]
AID - 10.3892/mmr.2016.5573 [doi]
PST - ppublish
SO  - Mol Med Rep. 2016 Sep;14(3):2397-404. doi: 10.3892/mmr.2016.5573. Epub 2016 Jul 
      28.